Inventor
KOLE RYSZARD
US28 patents
⚠️ This page may combine multiple inventors who share the name “KOLE RYSZARD”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SAREPTA THERAPEUTICS INC
19 patentsUS8865883B2Oct 21, 2014
Multiple exon skipping compositions for DMD
SAREPTA THERAPEUTICS INC95 citations98
US8835402B2Sep 16, 2014
Compound and method for treating myotonic dystrophy
SAREPTA THERAPEUTICS INC91 citations98
US9447417B2Sep 20, 2016
Multiple exon skipping compositions for DMD
SAREPTA THERAPEUTICS INC61 citations97
US9447416B2Sep 20, 2016
Multiple exon skipping compositions for DMD
SAREPTA THERAPEUTICS INC40 citations97
US9434948B2Sep 6, 2016
Multiple exon skipping compositions for DMD
SAREPTA THERAPEUTICS INC52 citations97
US9234198B1Jan 12, 2016
Multiple exon skipping compositions for DMD
SAREPTA THERAPEUTICS INC35 citations97
US9453225B2Sep 27, 2016
Multiple exon skipping compositions for DMD
SAREPTA THERAPEUTICS INC23 citations92
US9833468B2Dec 5, 2017
Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
SAREPTA THERAPEUTICS INC12 citations91
US9326992B2May 3, 2016
Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
SAREPTA THERAPEUTICS INC16 citations91
US11071749B2Jul 27, 2021
Oligonucleotide analogues targeting human LMNA
SAREPTA THERAPEUTICS INC3 citations84
US9066967B2Jun 30, 2015
Oligonucleotide analogues targeting human LMNA
SAREPTA THERAPEUTICS INC4 citations84
US10927378B2Feb 23, 2021
Compound and method for treating myotonic dystrophy
SAREPTA THERAPEUTICS INC1 citations73
US10106796B2Oct 23, 2018
Compound and method for treating myotonic dystrophy
SAREPTA THERAPEUTICS INC3 citations73
US10076536B2Sep 18, 2018
Oligonucleotide analogues targeting human LMNA
SAREPTA THERAPEUTICS INC2 citations73
US10822608B2Nov 3, 2020
Oligonucleotide analogues targeting human LMNA
SAREPTA THERAPEUTICS INC2 citations71
US11236329B2Feb 1, 2022
Compound and method for treating myotonic dystrophy
SAREPTA THERAPEUTICS INC0 citations62
US9682097B2Jun 20, 2017
Oligonucleotide analogues targeting human LMNA
SAREPTA THERAPEUTICS INC1 citations62
US11802283B2Oct 31, 2023
Oligonucleotide analogues targeting human LMNA
SAREPTA THERAPEUTICS INC0 citations61
US10398721B2Sep 3, 2019
Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
SAREPTA THERAPEUTICS INC0 citations50
UNIV NORTH CAROLINA
4 patentsUS5976879ANov 2, 1999
Antisense oligonucleotides which combat aberrant splicing and methods of using the same
UNIV NORTH CAROLINA211 citations98
US5916808AJun 29, 1999
Antisense oligonucleotides which combat aberrant splicing and methods of using the same
UNIV NORTH CAROLINA198 citations98
US5665593ASep 9, 1997
Antisense oligonucleotides which combat aberrant splicing and methods of using the same
UNIV NORTH CAROLINA168 citations98
US5627274AMay 6, 1997
Antisense oligonucleotides which combat aberrant splicing and methods of using the same
UNIV NORTH CAROLINA179 citations98